SUBJECT INDEX

ACCESS procedures (see also Fistula and vascular prostheses)
and blood flow to limbs, 117
in children, 573

Acetate, relation to blood pressure drop during haemodialysis, 258, 265

Acidosis, metabolic, in CRF, 491

Acute Renal Failure (see Renal Failure, acute)

Age
bone and pubertal status, 109
mean, of new patients, 11
and patient survival, in children, 87
and patient survival on different treatments, 23, 28
and pubertal status, 109
and selection of patients for treatment, 13
and survival of grafts, 29

Albumin, conformation of in uraemia, 628
Aldosterone, levels and haemoperfusion, 604

Allergic reaction, to polycrylonitrile, 229
Allograft (see Renal Transplantation)

Alport’s syndrome, 36, 86

Alternate pathway (see Complement)

Aluminium
and anaemia, 160
compounds, use as phosphate binders, 556
and dialysis encephalopathy, 157, 562, 586
hydroxide administration, 533, 556
removal from water supplies, 159, 163, 561, 586
serum/dialysate relationship, 159
uraemic bone disease and, 160, 556, 562

Amino acid analogues, influence on urea cycle enzymes, 636

Amyloidosis, in Familial Mediterranean Fever, 506, 513

Anaemia
and aluminium toxicity, 160
and iron deficiency, 625
renal, and androgens, 136
and serum erythropoietin, 442, 444
uraemic haemolysis and increased susceptibility to peroxidation causing, 437

Androgens, in renal anaemia, 136

Ankylosing spondylitis and HLA system, 273, 277

Anticonvulsant therapy and Vitamin D metabolites, 549

Antihypertensive drugs, pharmacokinetics of, during intermittent dialysis, 607

Arteriovenous fistula (see also Vascular Prostheses)
in children, 324, 573
using synthetic conduits, 579

Azathioprine (see Immunosuppressive Drugs)

B LYMPHOCYTES (see Lymphocytes)

Balkan nephropathy as primary renal disease, 36

Beta-blockers, pharmacokinetics during haemodialysis, 607

Bicarbonate reabsorption in renal failure, 491

Biopsy, fine needle in diagnosis of rejection, 335

Births on dialysis and after renal transplantation, 64

Bleeding
gastrointestinal, 48, 361
pathogenesis of in uraemia, 418, 449

Blood
density and blood volume, 245

643
Blood (continued)
flow after access procedures, 117
pressure
after infusion of Saralasin, 412, 416
changes during ultrafiltration, 245, 253, 255, 258, 261
and relation to osmolality, 258, 261
transfusion
HLA system in, 275
and transplantation, 63, 87, 114
volume
and blood density, 245
during ultrafiltration, 247

Bone
age (see Children and growth)
disease
evolution in RDT patients, 639
ureamic and aluminium, 160, 556, 562, 586
loss (see also Renal Osteodystrophy)
cessation in renal failure using 1α
Hydroxy Vitamin D3, 517
mass, assessment from forearm mineral
content, 519
mineral content
effect of 1α Hydroxy Vitamin D3, 517
in patients on RDT, 517, 641
resorption and calcitonin, 524
Brain, urea synthesis in renal failure, 500
Bromocriptine and hormone changes on
haemodialysis, 184
Bumetanide, and tubuloglomerular feedback, 613
BUN (see Urea)

CADAVER
donors, 315, 325
grafts, significance of vascular anomalies, 345
graft survival, 29, 325
Calcification, soft tissue, pathophysiology
of, 552
Calcitonin
in patients with osteitis fibrosa, 524
and PTH hypersecretion, 551
Calcium
balance
on haemofiltration, 533, 538
in renal failure, 549
concentration in dialysate, 521, 560
deposit in conjunctiva, 373
plasma, response to Calcitonin, 527, 528, 529
Cancer (see Malignant disease)
Cardiac
failure as cause of death, 43

Cardiac (continued)
output during ultrafiltration and dialysis, 262
Cataracts, after renal transplantation, 372, 373
Catecholamines and blood pressure changes
during dialysis, 258, 265
Cell mediated immunity, 283
measurement using DNCB in haemodialysis
patients, 283, 310
Cellography (see Membranes)
Cerebral
urea synthesis, 500
vascular accident as cause of death, 40, 44,
89, 324
Children
arteriovenous fistula in, 573
chromosomes in, born of immunosuppressed
parents, 384
facilities for treating, 79
growth of,
and bone age, 107
on dialysis and after transplantation, 96
and peritoneal dialysis, 112
and puberty status, 96, 103, 108
and relation to body weight, 107
and steroids, 106
home dialysis of, 87
hypertriglyceridaemia in, 601
incidence of chronic renal failure in, 79
long term results in, 87, 322
new patients treated, 79
numbers treated, 79, 80
primary renal disease, 83, 323
rehabilitation of, on dialysis and after
transplantation, 94, 327
rejection of transplants in, 87
serum ferritin in, 625
survival on dialysis and after transplantation,
87, 322
Cholecalciferol (see Vitamin D)
Chromosomes of children born of immuno-
suppressed parents, 384
Cimetidine
in prevention of gastrointestinal complications, 361
in transplant patients, 361, 369
Clonidine, pharmacokinetics during dialysis, 607
Coagulation, intramuscular and FDP, 466
Colchicine in Familial Mediterranean Fever,
507, 511, 513
Complement
activation and leucopenia, 144
components after kidney transplantation, 289
Computed tomography (see Tomography)
Dialysis (continued)

patients, 639
e-Antigen in HB antigen positive, 306
evolution of bone disease in, 639
chronic hepatitis in, 596
immunisation against Hepatitis B, 66, 130
long term follow up,
results in, 20
results in children, 322
reduction of hypertriglyceridaemia in,
601
plasma
refilling rate in genesis of hypotension
during, 239
sampling without blood loss, and, 571
and pregnancy, 64
rehabilitation on, 69
staff and hepatitis B, 66, 130
strategies, 54
techniques, 60
time, 54, 260
treatment of psoriasis with, 171
Dietary manipulation of hypertriglyceridaemia, 601
Dihydroetachysterol (see also Vitamin D),
Dihydroxy Vitamin D3 (see Vitamin D)
Dinitrochlorobenzene skin test, 283
2,3 Diphosphoglycerate in renal anaemia,
140
Dipyridamole, in patients on dialysis, 209, 211
Donors
one thousand prospective cadaveric, 315
for children, 87, 325
primary vascular anomalies of kidney in,
345
Dopamine Beta Hydroxylase in haemofiltration
and haemodialysis, 610
Diuretics, effect on tubuloglomerular feedback,
613
Duodenal ulcer and renal transplantation,
361
E-ANTIGEN in hepatitis B positive patients, 306
EDTA Registry
report on dialysis and transplantation, 4
in children, 79
Electron microscope, scanning, study of
hyperacute rejection, 330
Encephalopathy
aluminium and dialysis, 62, 157, 562, 586
and water treatment, 62, 586
End stage renal failure (see renal failure)
Endoscopy in pre-transplant assessment,
362, 369

DEATH
after transplantation, 44
causes in children on dialysis, 93, 324
on dialysis, 40
due to malignant disease, 53
from gastrointestinal complications, 361
on peritoneal dialysis, 52
with a functioning transplant, 49
Decadurabolin (see Androgen)
Decomisation of water for dialysis, 62, 562,
586
Dementia, Dialysis (see Encephalopathy)
D-Glucaric acid as neurotoxin, 164
Diabetes
and HLA system, 273, 276, 277
and peritoneal dialysis, 205
and selection for treatment, 13, 16, 17
Dialysate
calcium concentration, 560
magnesium concentration, 561
Dialysed males, serum hormone concentration in,
599
Dialysers, re-use of, 60
Dialysis (see also haemodialysis and peritoneal dialysis)
bone mass in patients on, 518
cardiac output and, 262
of children on, 94, 322, 327
computer control of, 588
death on, 40
dementia (see Encephalopathy)
gastrointestinal hormones in patients
treated by, 456
home (see Home Dialysis)
and intracocular pressure, 376
new techniques, 61
number of children alive on, 80

Computer control of dialysis therapy, 588
Coronary artery disease and transplantation,
144 (see also Myocardial infarction)
Cramps, muscle during haemofiltration, 233
Cuprophan (see Membranes)
Cyclophosphamide (see also Immunosuppressive drugs)
spermatogenesis and, 388
Cystic kidney disease, 36, 86
and bone mass, 519
and computed tomography, 617
Cystinosis, 36, 86, 93
Cyto genetics of children born of immunosuppressed parents, 384
Cytomegalovirus infection, 352, 375
Cytotoxic cells and rejection, 335
Cytotoxicity, cellular modulation by methylprednisolone, 299
Erythrocytes
suscettibility to peroxidation in uraemia, 437
glucose utilisation by, 630
Erythropoietin
effect of androgen therapy, 140, 143
and inhibitors in serum, 447
negative feedback between haematocrit
and, 442
serum levels in uraemia, 140, 141
Essential amino acids (see Amino acids)
Europe
centres for dialysis and transplantation, 12
growth of transplantation in, 10
new patients according to country, 11
selection of patients according to country, 13
treatment of children in, 79
Extracellular fluid volume and bicarbonate
reabsorption, 491

FACILITIES for children (see Children)
Failure, primary graft and vascular anom-
alias, 345
Factor VIII and uraemic bleeding, 449
Familial Mediterranean Fever
and amyloidosis, 506
microscopy of kidney in, 508
nephrotic syndrome in Turkey, 506
Feedback
between haematocrit and erythropoietin, 442
hypothalamic in renal failure, 600
tubuloglomerular, 613
Ferritin, serum concentration in renal
failure, 625
Fertility on haemodialysis, and hormone
changes, 178
Fibrin degradation products
in hyperacute rejection, 330
urinary, 466
Fistula arteriovenous
blood flow to limbs after, 117
septicaemia and, 42
Flow of patients in Registry, 4
Fluid overload and isolated ultrafiltration,
267
Fluoride and encephalopathy, 26
Follicle stimulating hormone
in haemodialysis, 178, 599
serum concentration in males with renal
failure, 599
Frusemide, effect on tubuloglomerular feed-
back, 613
Function, recovery of in patients in chronic
renal failure, 64

GASTRIC
erosions
in acute renal failure, 464
and renal transplantation, 361
function and transplantation, 361
Gastrin levels
and haemoperfusion, 604
in renal failure, 459
Gastrointestinal
complications after transplantation, 361
hormones in renal failure, 456
Geographical variation in causes of renal
failure, 36
Glaucoma, steroid, 375
Glomerulonephritis
and FDP, 466, 467
HBsAg immune complex, 473
natriuretic material in, 424
as primary renal disease, 36, 86, 323
response to saline load, 432
tubular changes in, 483
Glucagon in renal failure, 459
Glucose utilisation by erythrocytes, 630
Glycerol-induced acute renal failure, pro-
tection against with reduced renal mass,
402
Gonadal hormones, serum concentrations of
in renal failure, 599
Graft (see Renal transplantation)
parathyroid autograft, 540, 565
PTFE (see Vascular Protheses)
 survival, 29, 87
and cell mediated immunity, 283
Growth (see Children)

HAEMATOCRIT
fall in, as sign of graft rupture, 379
and serum erythropoietin, 442
Haemodialysis
changes in body fluid volumes during, 257
in children, 79, 323
comparison with haemofiltration, 228
comparison with peritoneal dialysis in
diabetic nephropathy, 205
conditions to prevent osteodystrophy, 563
controlled sequential ultrafiltration and,
239, 245, 253, 260
effect of single, on fasting hormone levels,
459, 462
leucopenia and, 144
and menstrual disturbance, 178
pharmacokinetics of antihypertensive
drugs, 607
use of subclavian vein for acute, 575
sympathetic activity in, 252, 610
and thyroid function, 619
Haemodialysis (continued)
thyroid hormones in, 191
ultrafiltration during, 245
without heparin, 122
Haemodynamics (see also Blood pressure,
Blood volume, Cardiac output)
changes in acute renal failure, 406
and osmolality changes, 250
and ultrafiltration, 249
Haemofiltration
comparison with haemodialysis, 228
cramps in, 233
and hypertensive episodes, 233
and osteodystrophy, 563
and secondary hyperparathyroidism, 532
with sorbent regeneration of ultrafiltrate,
220, 245
sympathetic activity in, 610
and thyroid function, 187
treatment with, 61
Haemolysis, uraemic, peroxidation and,
437
Haemolytic uraemic syndrome, 86
Haemoperfusion
adsorption of creatinine at pulsatile flow,
593
new techniques, 61
and plasma levels of hormones and β
methyl digoxin, 604
with sorbent membranes, 591
Haemorrhage
as cause of death, 45, 46, 47, 48
gastrointestinal, 45, 46, 47, 48
Heart failure, use of ultrafiltration in, 267
Henoch Schonlein nephritis, 86
Heparin
haemodialysis without, 122
osteoporosis due to, 562
Hepatic
changes in HBsAg positive patients, 309
cirrhosis, use of ultrafiltration in, 267
protein synthesis, 636
urea synthesis, 500, 636
Hepatitis, 66, 306, 473
chronic, 596
in dialysis staff, 68, 130, 131, 306
HBsAg immune complexes, 473
long term follow up, 596
role of hepatotoxic drugs, 596
B antigen, 596
active immunisation against, 66
e antigen in serum of positive patients
with, 306
immune complex glomerulonephritis,
473
passive immunisation against, 66, 130
percentage of positive patients, 66
Hepatitis (continued)
positive haemodialysis patients, long
term follow up, 596
response to and graft survival, 32
Hepatotoxic drugs, role in chronic hepatitis,
596
Hereditary nephropathy, 86
Hexose-monophosphate shunt in erythro-
cytes, 630
Histocompatibility system (see also HLA
system)
major complexes, 278
HLA system, antigens, 273
and cadaveric donors, 315
clinical and biological significance of, 273
DR typing, 274, 282
relation to disease susceptibility, 273, 276
role in organ transplantation, 275
and transplant outcome, 287
Hollow fibre dialyser and duration of
dialysis, 56
Home dialysis, 4, 7, 9, 27, 87, 324
Hormones (see also Individual hormones)
in chronic renal failure, 599, 619
gastrointestinal in renal failure, 456
gonadal in renal failure, 599
on haemodialysis, 599, 619
levels, influence of haemoperfusion, 604
pituitary in renal failure, 599
sex hormone changes and menstrual dis-
turbances, 178
thyroid, in haemofiltration, 187
Human growth hormone levels, influence of
haemoperfusion, 604
Hydroxy cholecalciferol (see Vitamin D
analogues)
1α Hydroxy Vitamin D3 (see Vitamin D
analogues)
1,25 Hydroxvitamin D3 (see Vitamin D
analogues)
25 Hydroxy Vitamin D3 (see Vitamin D
analogues)
Hypercalcemia, after parathyroid auto-
graft, 545
Hyperkalaemia
as cause of death, 42, 50
and sequential ultrafiltration, 266, 270
Hyperlipoproteinaemia
in chronic renal failure, 601
and ocular changes, 375
Hyperparathyroidism (see also Osteitis
fibrosa)
and calcium deposits in eye, 373
and haemofiltration, 532
and optimal range for plasma phosphate,
556
osteosclerosis in, 547
Hyperparathyroidism (continued)
in patients on dialysis, 641
parathyroidectomy for, 540

Hyperphosphataemia
on haemofiltration, 229, 235
and PTH secretion, 549

Hypertension
effect of Saralasin, 412
and sympathetic activity, 610

Hypertriglyceridaemia, reduction of in
dialysed patients, 601

Hypocalcaemia after parathyroidectomy, 541

Hypogonadism, role of testicular adenylate
cyclase, 622

Hypokalaemia and haemodynamics during
ultrafiltration, 250

Hypotension
during dialysis, plasma refilling rate and,
239, 257, 260
in haemofiltration compared with haemo-
dialysis, 233
and plasma volume, 242, 247

Hypovolaemia
during dialysis, plasma refilling rate and,
239
and hypotension, 239, 244, 260, 270

Immune complexes
HBsAg and glomerulonephritis, 473
in kidney in Familial Mediterranean Fever,
508, 512
after renal transplantation, 289
and tubular lesions, 484

Immune response (Ir) Determinants, 274

Immunisation
active, against Hepatitis B, 66
passive, against Hepatitis B, 66, 130

Immunosuppressive drugs
cytogenetics of children born of parents
on, 384
modulation of cellular cytotoxicity by, 299

Infection
in dialysis patients, 42
in renal transplant patients, 47
urinary tract and FDP, 467

Insulin
influence of haemoperfusion, 604
levels, in renal failure, 459, 604

Integrated therapies and survival, 25

Intensive care units and kidney donors, 316

Intermittent dialysis (see Dialysis, Haemo-
dialysis)

Iron
deficiency in chronic renal failure, 625
stores in chronic renal failure, 625

Isolated ultrafiltration (see Ultrafiltration
without dialysis)

K Cells (see Lymphocytes)
Keto analogues of essential amino acids, 636

Kidney (see also Renal Graft)
donors, 315
rupture of allograft, 378
transplantation (see Renal Transplanta-
tion)

Leucocyte
antigens (see HLA system)
sequestration in lung during dialysis, 144,
150

Leucopenia
and cytomegalovirus infection, 352
haemodialysis-induced, 144

Limbs, blood flow after access procedures,
117

Live donor graft survival, 29

Liver (see also Hepatic and Hepatitis)
biopsies in long term follow-up, 596

Luteinising hormone
changes on haemodialysis, 178, 599
serum concentration in males with renal
failure, 599

Lymphocytes, B and T in immune reaction,
278, 299

Lymphocyte-mediated cytotoxicity assay,
effect of Methyl prednisolone on, 299

Magnesium
balance in haemofiltration, 532
in dialysate, 561

Malignant disease
comparison of results of treatment of
renal failure with, 20, 318
death due to, 53

Medullary cystic disease (see Cystic Kidney
Disease)

Membranes
activation of complement by, 144
cellophane and complement activation, 144
a synthetic for haemofiltration, 229
cuprophan, and dialysis strategy, 56
and complement activation, 145
high flux, use for ultrafiltration, 261
polyacrylonitrile, and dialysis strategy, 56
and complement activation, 145
in controlled sequential ultrafiltration,
240, 261
for haemofiltration, 229
polycarbonate and complement activation,
145
Menstrual disturbances, sex hormone changes and, 178
Methylprednisolone, modulation of cellular cytotoxicity by, 299
β-Methyl digoxin, haemoperfusion and plasma levels of, 604
Middle molecules and erythrocytes susceptibility to peroxidation, 439, 441
in polynucleitr, 164
removal during haemofiltration, 234
synthesis of, in rat tissues, 633
Mineralisation front and Vitamin D metabolites, 551
Mixed lymphocyte culture, effect of Methyl prednisolone on, 299
Mongolism and parents treated with immunosuppressive drugs, 384
Multiple sclerosis and HLA system, 273, 276, 281
Myocardial infarction as cause of death, 42, 45, 46
comparison of survival with end stage renal failure, 20
in diabetes, 209
and transplantation, 511
Myo-inositol, as neurotoxin, 164

NANDROLONE (see Androgen)
Natriuretic material, renal origin of, 424
Needle, fine aspiration cytology in acute rejection, 335
Nephrectomy, partial in protecting against acute renal failure in rats, 402
Nephritis (see Glomerulonephritis)
Nephrocalcinosis as primary renal disease, 36
Nephron loss and bicarbonate reabsorption, 491, 498
Nephronophthisis as primary renal disease, 86
Nephropathy (see also Renal disease) analgesic and drug induced, 36
Balkan, 36
reflux and HLA typing, 281
Nephrotic syndrome natriuretic material in, 424, and familial Mediterranean Fever, 506
use of ultrafiltration in, 267, 269
Nephrotic serum nephritis, sodium excretion in rats with, 424
Neuromuscular abnormalities and renal osteodystrophy, 553
Neuropathy (see Polyneuropathy)
Neurotoxin, plasma in uraemic polyneuropathy, 164
Noradrenaline during ultrafiltration, 258, 265
Nutrition, relation to growth in children on dialysis, 107, 111

OCULAR changes and transplantation, 372
Oestradiol, changes in haemodialysis, 178
Ornithine cycle and urea production, 500
Osmolality changes during haemodialysis, 229, 250, 253, 261
during ultrafiltration, 250
on haemofiltration, 229
effect on plasma refilling rate during ultrafiltrate, 242, 243
relation of blood pressure to plasma, 255, 258, 265
Osmosis, reverse (see Reverse osmosis)
Osteitis fibrosa and calcitonin, 524
in renal osteodystrophy, 547
Osteodystrophy (see also Renal Osteodystrophy) aluminium and, 159, 586
Osteomalacia pathophysiological mechanism in renal, 551
in renal osteodystrophy, 547
and serum aluminium, 586
Osteopenia in chronic renal failure, 518, 521
Osteosclerosis in renal osteodystrophy, 547
Ovulation and hormone changes on haemodialysis, 178, 180
Oxalosis as primary renal disease, 86
survival of children with, 86, 89, 504

PAEDIATRIC (see Children)
Pan membranes (see Membranes)
Parathyroid hormone and bicarbonate excretion, 491, 498
and calcitonin in osteitis fibrosa, 524
levels haemofiltration and, 533
haemoperfusion and, 604
and neuromuscular abnormalities, 553
after parathyroid autograft, 540
in uraemia, 549, 551
after treatment with 1α OH D3, 521
Parathyroidectomy with autograft, 540, 565
and renal osteodystrophy, 564
in treatment of secondary hyperparathyroidism, 540
Pathogenesis of tubular renal disease, 483
Pathogenic factor in serum of patients with acute renal failure, 393
Pentagastrin tests, 361
Pepitic ulcer
management of prior to transplantation, 362
and renal transplantation, 361
Pericarditis as cause of death, 42, 43
Peripheral resistance changes during dialysis and ultrafiltration, 258, 262
Peritoneal dialysis
causes of death on, 52
continuous ambulatory, 197
costs, 203
death on, 52
in diabetic nephropathy, 205
and growth, 112
home, 9
intermittent, 9
intermittent, comparison with continuous, 197
and renal osteodystrophy, 563
with sorbent regeneration, 213
Peritonitis, in peritoneal dialysis, 198, 201, 209, 210
Peroxide avoidance of compounds producing, in uraemia, 290
Peroxidation and uraemic haemolysis, 437
Pharmacokinetics of antihypertensive drugs, 607
Phosphate
binders, use in osteodystrophy, 533, 556
elimination on haemofiltration, 533
enriched dialysate, 561
levels after calcitonic, 526
levels and PTH secretion, 549
plasma, optimal range of, 556
restriction in treatment of osteodystrophy, 555
Piretanide and tubuloglomerular feedback, 613
Pituitary hormones in renal failure, 599
Plasma
refilling rate
during ultrafiltration, 239
measurement of, 240
sampling in dialysis patients without blood loss, 571
volume
in dialysis, 239
effect of ultrafiltration on, 23
plasma refilling rate and, 239
Platelet
extraction by dialysis, 124
function in uraemic bleeding, 449
in hyperacute rejection, 330
Platelet (continued)
inhibition of function (see Prostacyclin)
Polyacrylonitrile (see also Membranes)
possible allergic reaction to, 229
Polycarbonate (see Membranes)
Polycystic disease (see Cystic kidney disease)
Polyneuropathy
diabetic in dialysis treatment, 208, 210
differentiation from osteodystrophy associated abnormalities, 553
uraemic, plasma neurotoxin in, 164
Postural hypotension, in peritoneal dialysis, 201
Potassium
(see also Hyperkalaemia and Hypokalaemia), 491
body stores and bicarbonate reabsorption, 491
Prednisolone (see Steroids)
Pregnancy on dialysis and after transplantation, 64
Progesterone, changes on haemodialysis, 178
Prolactin, changes on haemodialysis, 178
Propranolol during intermittent dialysis, 607
Prostacyclin
activity in uraemia, 450
and aspirin treatment, 453
enhanced availability from blood vessels, 418
in haemodialysis, used instead of heparin, 122
instability of, 129
Protein
losses in peritoneal dialysis, 202
synthesis
influence of amino acid analogues on, 636
in uraemic rats, 636
Pruritus, parathyroidectomy and, 564
Psoriasis
effect of parathyroidectomy, 173, 176
treatment with dialysis, 171
Pubertal status
in dialysis and transplantation, 108, 109
and growth, 98
during treatment for renal failure, 109
Pulmonary embolus in transplant patients, 44
Pyelonephritis
appearance in computed tomography, 617
immunological reactions, 483
as primary renal disease, 36, 86
RADIATION, therapy and parenthood, 389
Radiographical abnormalities in renal failure, 554
Recovery of function in chronic renal failure, 64
Recurrence of primary renal disease after transplantation, 40
Regrafting, 16, 20
Rehabilitation
- of patients on dialysis, 69
  after transplantation, 69
  of children, 94, 327
Rejection (see Renal transplant rejection)
Renal disease
  causes of in Europe, 36
  computed tomography as aid to diagnosis in, 617
  rarer types of, 39
  recurrence of, after transplantation, 40
  variation in geographical distribution of, 36
Renal failure, acute
  causes, 393, 402
  and computed tomography, 617
  partial protection with reduced renal mass, 402
  pathogenic factor in serum, 393
  use of subclavian vein for dialysis, 575
bicarbonate reabsorption in, 491
calcitonin in patients with osteitis fibrosa and, 524
cell mediated immunity in, 283
cerebral and hepatic urea synthesis in, 500
cessation of bone loss by 1α hydroxyvitamin D₃, 577
chronic, recovery of function in, 64
diagnosis of, 36
  in children, 83, 323
gastrointestinal hormones in, 456
glucose utilisation by erythrocytes in, 630
hypogonadism of, and testicular adenylate cyclase, 622
serum
  erythropoietin in, 442
  ferritin in children with, 625
  hormone concentration in males with, 599
thyroid function in, 619
function, measurement with EMI whole body scanner, 618
mass: reduced in partial protection against ARF, 402
Renal (continued)
osteodystrophy (see also Vitamin D, parathyroid)
in advanced renal insufficiency, 554
aluminium and, 160, 586
bone mineral content and, 517
current status of management, 547
evolution in RDT patients, 639
in haemofiltration, 535
indications for parathyroidectomy, 564
management during maintenance dialysis, 560
management when not detectable on X-ray, 559
management in mild renal insufficiency, 553
trial of 1α hydroxy vitamin D₃, 517
transplantation
ALG treatment, 292, 297
and allograft ruptures, 378
e-antigen in HBsAg positive patients after, 306
and blood transfusion (see blood transfusion)
cadaveric donors, 315
cellular cytotoxicity and, 299
in children, long term results, 322
complement, components after, 289
computed tomography as aid to diagnosis in, 617
death after, 44
effect on gastrointestinal hormones, 489
effect on menstrual disturbances of haemodialysis, 182
gastrointestinal complications after, 361
and hepatitis, 32
human polyoma virus in, 352
and immune complexes after, 289
ocular findings after, 372
predictive factor for outcome, 283
pregnancy after, 64
radiation therapy and parenthood, 389
rates in different countries, 8
recurrence of primary renal disease after, 40
rehabilitation after, 69, 94, 327
rejection
  acute, fine needle biopsy in diagnosis, 335
  crises and intraocular pressure, 374
  and FDP, 466
  hyperacute in rat, 330
  and immune complexes, 289, 297
  and polyoma virus in, 353, 357
  rate in children, 87
reaction and complement components, 292
  and response to hepatitis infection, 32
Renal (continued)
significance of vascular anomalies, 345
and thyroid function, 619
and time on dialysis, 30
tubular disease (see Tubular)
tumours and computed tomography, 617
Renin, plasma
effect of haemoperfusion, 604
effect of Saralasin, 412
Retinopathy, diabetics on dialysis treatment, 208, 209, 210
Reverse Osmosis in water treatment for
dialysis, 62, 562, 586
Rupture of allografted kidney, 378
Reuse of dialysers, 60

SARALASIN
effect on blood pressure, 412, 416
PRA and arginine-vasopressin and, 412
Secretin, levels in chronic renal failure, 459, 462
Seldinger’s technique for cannulation of subclavian vein, 575
Selection of patients for treatment, 13
Septicaemia
and arteriovenous fistula, 42
as cause of death, 42, 43, 50, 93
Sequential treatment (see Ultrafiltration)
Sequential ultrafiltration (see Ultrafiltration)
Sex hormones (see Hormones)
Sodium
concentration in dialysis, 253
depletion and natriuretic factor, 424
reabsorption of, in glomerulonephritis, 424
Sorbent
membranes and haemoperfusion, 591
regeneration of
peritoneal dialysate, 213
ultrafiltrate in haemofiltration, 220
Steroid (see also Methylprednisolone)
alternate day therapy, 105, 106
cytogenetics of children born of immuno-suppressed parents, 384
dosage, effect on growth, 106
and gastrointestinal complications, 366, 369, 370
glaucoma, 375
in nephrotic syndrome and FDP, 467, 468
and ocular complications after transplantation, 373
Stock of patients on Registry, 4
Subclavian vein for acute haemodialysis, 575
Subconjunctival haemorrhage in uraemia
and after transplantation, 373
Survival (see also Renal Transplantation, Children, Dialysis)
and age, 28
calculation, and integrated therapies, 25
of children, 87
comparison of dialysis and transplantation with common cancers, 20
comparison with myocardial infarction, 20
cumulative, 27
effect of patient age, 28, 30
graft, 29, 87
of patients, 20
in rarer causes of renal failure, 89
rates of patients with diabetic nephropathy, 211
Sympathetic activity in haemofiltration and haemodialysis, 252, 258, 265, 610

TESTICULAR adenylate cyclase in renal insufficiency, 622
Testosterone
changes on haemodialysis, 177, 599
in renal anaemia, 143
serum concentrations in dialysed males, 599
Thioinosinic acid and the foetus, 389
Thyroid
function in
chronic renal failure, 619
haemodialysis and transplant patients, 599
haemofiltration, 187
hormone concentrations
in males with renal failure, 599
influence of haemoperfusion, 604
Tissue typing
kidney donors and, 315
in familial Mediterranean Fever, 511
T-lymphocytes (see Lymphocytes)
Tomography, computed as an aid to diagnosis, 617
Transfusion (see Blood Transfusion)
Tubular renal disease, pathogenetic mechanisms, 483
Tubuloglomerular feedback
and acute renal failure, 394
effect of diuretics, 613
Tumours (see Malignant disease)

ULTRADIFFUSION
blood volume during, 247
haemodynamic reactions during, 245
Ultrafiltration
and blood pressure changes, 2, 253, 255
and blood volume, 247
cardiac output and, 262
equipment for, 261, 266
in haemofiltration compared with
haemodialysis, 233
and high sodium dialysis, 253
sequential, importance of plasma refilling
rate in genesis of hypotension, 239
as treatment technique, 61
timing of, 262
without dialysis, 245, 253, 261

Uraemia
abnormal confirmation of albumin in, 628
bleeding in, 418, 449
depressed immunity, 286
due to graft failure, 45
and gastrointestinal complications, 361
haemolysis in, 437
Uraemic rats, urea cycle enzymes and protein
synthesis in, 636

Urea
cycle enzymes, influence of essential
amino acid analogues in, 636
intestinal degradation of, 503
synthesis, cerebral and hepatic in renal
failure, 500
Ureteric stenosis and human polyoma
virus, 358, 359

Urinary
cytology, polyoma virus in, 353
leak and vascular anomalies, 348
tract infection and FDP, 467

VASCULAR
access
in children, 324, 573
complications using subclavian vein, 577
polished carbon button and synthetic
conduits, 579
subclavian vein as, 575
accidents, as cause of death, 42, 44, 45
anomalies in renal transplantation, 345
factors in uraemic bleeding, 418, 449
instability and acetate, 265
during dialysis, 261

Vascular (continued)
prostheses
access using polished carbon button, 579
choice of fistula needles for, 585
pathomorphological findings in, 582
in small children, 573
Vasoactive intestinal peptide, levels in renal
failure, 459
Vasopressin, effect of Saralasin on PRA in
hypertension, 412

Virus
cytomegalovirus (see Cytomegalovirus)
Human polyoma in renal transplantation, 352

Vitamin D
acquired resistance to, 549
administration in haemofiltration, 536
analogues in therapy, 558
1,25 Dihydroxyvitamin D3, 517, 549
lack and calcium malabsorption, 549
lack and osteomalacia, 551
24,25 Dihydroxy vitamin D3, possible
role, 550

1α Hydroxyvitamin D3
in therapy, 517, 525, 557
and plasma levels of Calcitonin, 525
and plasma levels of iPTh, 525
25 Hydroxyvitamin D3, 549
haemofiltration and levels of, 532
haemoperfusion and levels of, 604
hydroxylation of, in therapy, 557
effectiveness, and dosage of steroids in
osteodystrophy, 557

WARTS on immunosuppressive therapy, 375

Water
preparation for dialysis, 61, 157
treatment (see also Reverse osmosis)
aluminium removal by, 159, 163, 586
deioniser for, 62, 586
and dialysis encephalopathy, 62, 157, 586
water softening for, 62, 586

Weight, body and dialysis strategy, 58, 59
Wilm's tumour, 94

133 XENON, for measuring blood flow, 118